Novo Nordisk pushes insurers as weight-loss drug demand soars
#Wegovy #InsuranceCoverageNovo Nordisk pushes insurers to cover Wegovy costs, seeking balance with direct sales. Demand soars for obesity drugs despite employer pushback. Medicare pilot launching in July offers $50 monthly access, aiming to solve cost trend concerns. read more
Novo Nordisk Confident Despite Trump Tariff Risk, Sales Surge
#NovoNordisk #WegovySales of Novo Nordisk's weight-loss drug Wegovy surged by 86% last year, leading to higher-than-expected revenues. Despite concerns over potential Trump tariffs, the company remains confident in its ability to meet demands. Novo is now Europe’s most valuable company amidst soaring demand for anti-obesity treatments. read more
FDA Declares Ozempic and Wegovy Available After Years-Long Shortage
#Ozempic #WegovyAfter over two years of shortages, weight loss and diabetes drugs Ozempic and Wegovy are now considered "available" by the FDA. Sparking high demand, these injections are produced by Novo Nordisk, with increased availability due to their investment in capacity. read more